Literature DB >> 883468

'Enteral' hyperoxaluria. Effect of cholestyramine, calcium, neomycin, and bile acids on intestinal oxalate absorption in man.

W F Caspary, J Tönissen, P G Lankisch.   

Abstract

The effect of oral administration of cholestyramine, neomycine, calcium, and bile acids on intestinal 14C-oxalate absorption and urinary oxalate excretion was assessed in patients with normal or increased ('enteric' hyperoxaluria) urinary oxalate excretion. Cholestyramine, neomycine and acute administration of chenodeoxycholic acid (2.75 g/24 h) did not affect significantly 14C-oxalate absorption or urinary oxalate excretion. Oral administration of calcium markedly reduced 14C-oxalate absorption (88.2%) and urinary oxalate excretion (46%). Calcium-induced reduction of intestinal oxalate absorption was more pronounced in patients with hyperabsorption of oxalate than in subjects with normal oxalate absorption or excretion. Patients on treatment with high doses of chenodeoxycholic acid (1.5-2.0 g/day) for dissolution of cholesterol gallstones had increased oxalate absorption and excretion, patients on long-term treatment with lower doses of chenodeoxycholic acid (0.75-1.0 g/day) exhibited normal absorption or urinary excretion of oxalate. The results do suggest that calcium and bile acids do play an important role in the pathogenesis of 'enteric' hyperoxaluria. It is suggested that the beneficial therapeutic effect of cholestyramine in hyperoxaluria due to ileal resection is rather caused by its bile acid binding property than by direct binding of oxalate within the intestinal lumen.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 883468

Source DB:  PubMed          Journal:  Acta Hepatogastroenterol (Stuttg)        ISSN: 0300-970X


  9 in total

1.  Guidelines for management of patients with a short bowel.

Authors:  J Nightingale; J M Woodward
Journal:  Gut       Date:  2006-08       Impact factor: 23.059

Review 2.  Management of patients with a short bowel.

Authors:  J M Nightingale
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

Review 3.  Enteric hyperoxaluria: an important cause of end-stage kidney disease.

Authors:  Lama Nazzal; Sonika Puri; David S Goldfarb
Journal:  Nephrol Dial Transplant       Date:  2015-02-20       Impact factor: 5.992

Review 4.  Dietary Management of Chronic Kidney Disease and Secondary Hyperoxaluria in Patients with Short Bowel Syndrome and Type 3 Intestinal Failure.

Authors:  Maciej Adler; Ewen C Millar; Kevin A Deans; Massimo Torreggiani; Francesca Moroni
Journal:  Nutrients       Date:  2022-04-14       Impact factor: 6.706

Review 5.  The management of patients with enteric hyperoxaluria.

Authors:  John R Asplin
Journal:  Urolithiasis       Date:  2015-12-08       Impact factor: 3.436

6.  [Enteric hyperoxaluria. I. Intestinal oxalate absorption in gastrointestinal diseases (author's transl)].

Authors:  W F Caspary; J Tönissen
Journal:  Klin Wochenschr       Date:  1978-06-15

7.  Pathophysiology and Treatment of Enteric Hyperoxaluria.

Authors:  Celeste Witting; Craig B Langman; Dean Assimos; Michelle A Baum; Annamaria Kausz; Dawn Milliner; Greg Tasian; Elaine Worcester; Meaghan Allain; Melissa West; Felix Knauf; John C Lieske
Journal:  Clin J Am Soc Nephrol       Date:  2020-09-08       Impact factor: 8.237

8.  Risk Factors for Kidney Stone Formation following Bariatric Surgery.

Authors:  Megan Prochaska; Elaine Worcester
Journal:  Kidney360       Date:  2020-12-31

Review 9.  The metabolic and ecological interactions of oxalate-degrading bacteria in the Mammalian gut.

Authors:  Aaron W Miller; Denise Dearing
Journal:  Pathogens       Date:  2013-12-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.